Your browser doesn't support javascript.
loading
The role of biologics in treatment of ANCA-associated vasculitis.
Dharmapalaiah, Chethana; Watts, Richard A.
Afiliación
  • Dharmapalaiah C; Department of Rheumatology, Ipswich Hospital NHS Trust, Heath Road, Ipswich, IP4 5PD, UK.
Mod Rheumatol ; 22(3): 319-26, 2012 Jun.
Article en En | MEDLINE | ID: mdl-22038317
The vast majority of patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) who receive conventional treatment with glucocorticoids and cyclophosphamide experience frequent relapses and treatment-related side-effects. Increasing knowledge of the pathogenesis of AAV has permitted the development of targeted therapies against tumour necrosis factor (TNF)-α and T and B lymphocytes. Therapy with TNF-α blocking drugs has so far proved disappointing, and this approach is not recommended. B cell depletion using rituximab is effective for remission induction, especially in refractory patients. The long-term side-effects and the best method of using rituximab to maintain remission are still to be determined.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Receptores del Factor de Necrosis Tumoral / Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos / Anticuerpos Monoclonales de Origen Murino / Inmunosupresores / Anticuerpos Monoclonales Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Mod Rheumatol Año: 2012 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Receptores del Factor de Necrosis Tumoral / Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos / Anticuerpos Monoclonales de Origen Murino / Inmunosupresores / Anticuerpos Monoclonales Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Mod Rheumatol Año: 2012 Tipo del documento: Article